Chapter 22. Molecular Epidemiology and Ethics: Biomarkers for Disease Susceptibility

  1. Chris Wild2,
  2. Paolo Vineis3 and
  3. Seymour Garte4
  1. Kirsi Vähäkangas

Published Online: 22 APR 2008

DOI: 10.1002/9780470725726.ch22

Molecular Epidemiology of Chronic Diseases

Molecular Epidemiology of Chronic Diseases

How to Cite

Vähäkangas, K. (2008) Molecular Epidemiology and Ethics: Biomarkers for Disease Susceptibility, in Molecular Epidemiology of Chronic Diseases (eds C. Wild, P. Vineis and S. Garte), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470725726.ch22

Editor Information

  1. 2

    Molecular Epidemiology Unit, Centre for Epidemiology and Biostatistics, The LIGHT Laboratories, University of Leeds, Leeds, UK

  2. 3

    Division Epidemiology Public Health and Primary Care, Imperial College London, London, UK

  3. 4

    Graduate School of Public Health, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

Author Information

  1. Department of Pharmacology and Toxicology, University of Kuopio, Kuopio, Finland

Publication History

  1. Published Online: 22 APR 2008
  2. Published Print: 11 APR 2008

ISBN Information

Print ISBN: 9780470027431

Online ISBN: 9780470725726

SEARCH

Keywords:

  • disease susceptibility biomarkers;
  • biomarker variation;
  • biomarker development and disease susceptibility;
  • genetic studies and ethical issues;
  • molecular epidemiology and society;
  • communication issues and biomarker studies;
  • multidisciplinary dialogue in bioethics

Summary

This chapter contains sections titled:

  • Introduction

  • Ethical aspects in biomarker development for disease susceptibility

  • Ethical aspects of biobanking

  • Molecular epidemiology and society

  • Conclusions

  • References